Bruker BioSpin announced the acquisition of the Bridge12 EPR Business on October 7, 2024. This strategic move expands Bruker's capabilities in Electron Paramagnetic Resonance (EPR) technology.
The acquisition is expected to enhance Bruker's offerings in high-performance scientific instruments and analytical solutions. Further details regarding the financial terms of the transaction were not disclosed in the announcement.
This addition aligns with Bruker's broader strategy to enable scientists and engineers in making breakthrough discoveries in life sciences and advanced materials.
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.